ALBRECHT DETLEF 4
4 · Satsuma Pharmaceuticals, Inc. · Filed Jul 2, 2020
Insider Transaction Report
Form 4
ALBRECHT DETLEF
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2020-07-01$4.56/sh+300$1,368→ 20,512 total - Sale
Common Stock
2020-07-01$26.99/sh−600$16,195→ 20,212 total - Sale
Common Stock
2020-07-01$25.69/sh−300$7,707→ 20,212 total - Exercise/Conversion
Common Stock
2020-07-01$4.56/sh+600$2,736→ 20,812 total - Exercise/Conversion
Common Stock
2020-07-01$4.56/sh+100$456→ 20,312 total - Sale
Common Stock
2020-07-01$27.81/sh−100$2,781→ 20,212 total - Sale
Stock Option (Right to Buy)
2020-07-01−1,000→ 69,468 totalExercise: $4.56Exp: 2029-05-16→ Common Stock (1,000 underlying)
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $25.35 to $26.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $26.60 to $27.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.